AU2018371177B2 — Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
Assigned to Immunic AG · Expires 2023-10-19 · 3y expired
What this patent protects
The present invention refers to a 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4- yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said com…
USPTO Abstract
The present invention refers to a 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4- yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).
Drugs covered by this patent
- Livtencity (MARIBAVIR) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.